Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ipsogen gets rights to develop IDH1/IDH2 diagnostics from Personal Genome

Executive Summary

Qiagen NV’s majority-owned oncology diagnostics division Ipsogen SA has licensed exclusive worldwide rights from Personal Genome Diagnostics Inc. (PGDx; cancer genetics start-up) to develop tests for mutations of the IDH1/IDH2 genes as indicators of brain cancer, acute myelogenous leukemia, and other tumors.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal

Related Companies